Further studies need to be done with PEO1, PEO4, and PEO6 cell lines to determine, between CD44 and CD133, which is a surface marker and which one provides stemness, or whether both have mixed properties in ovarian cancer stem cells along disease progression [32,39,41,42,43]. This evidence concerns the gene PROM1 and ovarian carcinoma.